[go: up one dir, main page]

MX2009008463A - Formulaciones biodisponibles de compuestos heterociclicos. - Google Patents

Formulaciones biodisponibles de compuestos heterociclicos.

Info

Publication number
MX2009008463A
MX2009008463A MX2009008463A MX2009008463A MX2009008463A MX 2009008463 A MX2009008463 A MX 2009008463A MX 2009008463 A MX2009008463 A MX 2009008463A MX 2009008463 A MX2009008463 A MX 2009008463A MX 2009008463 A MX2009008463 A MX 2009008463A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
oglemilast
bioavailable
relates
present
Prior art date
Application number
MX2009008463A
Other languages
English (en)
Inventor
Mahendra G Dedhiya
Rahul Surana
Suneel K Rastogi
Anil Chhetrry
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of MX2009008463A publication Critical patent/MX2009008463A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a las formulaciones farmacéuticas biodisponibles de compuestos heterocíclicos, tales como N-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metansulfonamido -dibenzo[b,d]furan-1-carboxamida (oglemilast) y las sales farmacéuticamente aceptables del mismo, a los procesos para su preparación y a los métodos de tratamiento utilizando los mismos. La presente invención también se refiere a las formas amorfas sustancialmente puras de los compuestos heterocíclicos tales como el oglemilast. La invención está particularmente dirigida a las formas de dosis oral farmacéuticas biodisponibles que contienen oglemilast amorfo.
MX2009008463A 2007-02-09 2008-02-08 Formulaciones biodisponibles de compuestos heterociclicos. MX2009008463A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88900907P 2007-02-09 2007-02-09
US89635307P 2007-03-22 2007-03-22
PCT/US2008/053368 WO2008100800A1 (en) 2007-02-09 2008-02-08 Bioavailable formulations of heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX2009008463A true MX2009008463A (es) 2010-01-27

Family

ID=39686385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008463A MX2009008463A (es) 2007-02-09 2008-02-08 Formulaciones biodisponibles de compuestos heterociclicos.

Country Status (9)

Country Link
US (1) US20080194638A1 (es)
JP (1) JP2010518114A (es)
AR (1) AR065297A1 (es)
BR (1) BRPI0806447A2 (es)
CA (1) CA2677649A1 (es)
CL (1) CL2008000424A1 (es)
MX (1) MX2009008463A (es)
TW (1) TW200846323A (es)
WO (1) WO2008100800A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575186B2 (en) * 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
WO2012099952A2 (en) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2015175502A2 (en) * 2014-05-12 2015-11-19 Palatin Technologies, Inc. Replacement therapy for natriuretic peptide deficiencies
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
CN105461728A (zh) * 2015-12-29 2016-04-06 中山大学 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备方法
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP3666254B1 (en) 2017-08-11 2024-12-04 Amorepacific Corporation Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
PL378813A1 (pl) * 2003-04-11 2006-05-29 Glenmark Pharmaceuticals S.A. Nowe związki heterocykliczne przydatne w leczeniu stanów zapalnych i zaburzeń alergicznych: sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki

Also Published As

Publication number Publication date
US20080194638A1 (en) 2008-08-14
BRPI0806447A2 (pt) 2011-09-06
JP2010518114A (ja) 2010-05-27
CA2677649A1 (en) 2008-08-21
AR065297A1 (es) 2009-05-27
CL2008000424A1 (es) 2008-08-18
TW200846323A (en) 2008-12-01
WO2008100800A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MX2009008463A (es) Formulaciones biodisponibles de compuestos heterociclicos.
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
NO20082496L (no) Pyrazinderivater
UA94901C2 (ru) Антибактериальные производные пиперидина
NO20090328L (no) Nye forbindelser 385
WO2006011050A3 (en) Pyridine derivatives
DE60224172D1 (de) Formanilid-derivative als beta2-adrenorezeptor-agonisten
MY149731A (en) Compounds
MX2009011816A (es) Derivados de piridina.
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
WO2007087548A3 (en) Chemical compounds
TW200745111A (en) New compounds
MXPA05010496A (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
MX2010000801A (es) Composicion farmaceutica mejorada que contiene antagonista de canal de calcio de dihidropiridina y metodo para su preparacion.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
TW200606164A (en) New compounds
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
EA200971017A1 (ru) Аминоалкоксиарилсульфонамидные соединения и их применение в качестве 5-нтлигандов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal